Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M611157200 on March 3, 2007

J. Biol. Chem., Vol. 282, Issue 17, 12583-12589, April 27, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/17/12583    most recent
M611157200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pickersgill, L.
Right arrow Articles by Yeaman, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pickersgill, L.
Right arrow Articles by Yeaman, S. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Key Role for Ceramides in Mediating Insulin Resistance in Human Muscle Cells*

Laura Pickersgill{ddagger}1, Gary J. Litherland{ddagger}, Andrew S. Greenberg§, Mark Walker{ddagger}, and Stephen J. Yeaman{ddagger}2

From the {ddagger}Institute of Cell & Molecular Biosciences and Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, United Kingdom and the §Obesity and Metabolism Laboratory, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts 02111-1524

Received for publication, December 5, 2006 , and in revised form, February 26, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Elevated non-esterified fatty acids, triglyceride, diacylglycerol, and ceramide have all been associated with insulin resistance in muscle. We set out to investigate the role of intramyocellular lipid metabolites in the induction of insulin resistance in human primary myoblast cultures. Muscle cells were subjected to adenovirus-mediated expression of perilipin or incubated with fatty acids for 18 h, prior to insulin stimulation and measurement of lipid metabolites and rates of glycogen synthesis. Adenovirus-driven perilipin expression lead to significant accumulation of triacylglycerol in myoblasts, without any detectable effect on insulin sensitivity, as judged by the ability of insulin to stimulate glycogen synthesis. Similarly, incubation of cells with the monounsaturated fatty acid oleate resulted in triacylglycerol accumulation without inhibiting insulin action. By contrast, the saturated fatty acid palmitate induced insulin resistance. Palmitate treatment caused less accumulation of triacylglycerol than did oleate but also induced significant accumulation of both diacylglycerol and ceramide. Insulin resistance was also caused by cell-permeable analogues of ceramide, and palmitate-induced resistance was blocked in the presence of inhibitors of de novo ceramide synthesis. Oleate co-incubation completely prevented the insulin resistance induced by palmitate. Our data are consistent with ceramide being the agent responsible for insulin resistance caused by palmitate exposure. Furthermore, the triacylglycerol derived from oleate was able to exert a protective role in sequestering palmitate, thus preventing its conversion to ceramide.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Obesity exerts a major impact on insulin resistance and is closely associated with type 2 diabetes (1). Two-thirds of individuals diagnosed with type 2 diabetes are overweight, and almost half are clinically obese (2), furthermore the risk of developing diabetes increases dramatically with the degree of obesity. The relationship between obesity and insulin resistance has led to the hypothesis that ectopic storage of fat in non-adipose tissues such as skeletal muscle under conditions of lipid oversupply is causal in the development of obesity-associated insulin resistance, and elevated intramyocellular triacylglycerol (IMTG)3 levels have been identified as a potential link between increased non-esterified fatty acid (NEFA) availability and insulin resistance. The molecular mechanism behind the coupling of IMTG content and insulin resistance is unclear, although it appears unlikely that a neutral lipid metabolite such as triacylglycerol (TG) directly impairs insulin action. Indeed, there is evidence that IMTG stores are elevated not only in insulin resistance but also in insulin-sensitive athletes (3). Hence it is generally believed that IMTG represents a surrogate for other lipid metabolites in muscle. This includes an increasing body of evidence that lipid intermediates such as diacylglycerol (DAG) and ceramides have direct effects on insulin signaling and glucose utilization.

DAG has been identified as a potential mediator of lipid-induced insulin resistance. DAG has been shown to accumulate, together with triacylglycerol, in peripheral tissues from insulin-resistant rodents (4), and to inhibit insulin action in various isolated tissues or cultured cells (5–8), including skeletal muscle (9, 10). However, other studies have reported that DAG is dispensable to the development of insulin resistance. Specifically, in one study in C2C12 myotubes, the saturated fatty acid (FA), myristate induced significant DAG synthesis while having no effect on insulin sensitivity (10).

The sphingomyelin derivative, ceramide, is another signaling molecule that has been implicated in several physiological events. Ceramide levels are elevated in muscle of insulin-resistant animals (4) and in skeletal muscle from obese, insulin-resistant humans (11). Ceramide has also been shown to induce insulin resistance in a variety of cultured cells (6, 12–14). Ceramide can become elevated in muscle both by activation of sphingomyelinase, which produces ceramide from the hydrolysis of sphingomyelin (15), and by de novo synthesis from palmitate (16). In C2C12 myotubes, palmitate increases ceramide content and inhibits downstream insulin-stimulated protein kinase B (PKB) phosphorylation (14). Incubation of these cells with short-chain ceramide analogues (C2-ceramide) mimics the effects of palmitate on insulin signaling, suggesting that ceramide generation from saturated fatty acids is sufficient to account for inhibition of insulin signaling. Furthermore, blocking de novo ceramide synthesis in palmitate-treated C2C12 myotubes negates the inhibitory effect of saturated NEFA toward PKB activation by insulin, while inducing ceramide accumulation augments the inhibitory effect of saturated NEFA (17). Similar inhibition of PKB phosphorylation has been observed in other cell types exposed to C2-ceramide, resulting in diminished insulin-stimulated glucose uptake in muscle and fat cells (6, 7, 10).

To further investigate the roles of the various lipid metabolites in inducing insulin resistance, we have used a variety of methods to manipulate their levels in cultured human myoblasts. The effects of these manipulations on insulin sensitivity were investigated in an attempt to further define the relationship between IMTG and the development of insulin resistance.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—Tissue culture plates were purchased from Greiner (Gloucestershire, UK) and pipettes from Starstedt (Leicester, UK). Culture media, penicillin/streptomycin, trypsin-EDTA, and fetal calf serum were from Invitrogen (Paisley, UK). Chick embryo extract was from Sera Laboratories International (Salisbury, UK). Oleic acid, palmitic acid, fatty acid-free bovine BSA, Oil Red O, myriocin, fumonisin-B1, ceramide standards, and chemicals not specified were from Sigma (Poole, UK). Pepstatin, antipain, and leupeptin were from Peptide Institute (Osaka, Japan). Actrapid® insulin was from Novo Nordisk (Copenhagen, Denmark). Cell-permeable C2-ceramide analogues were from Tocris (Bristol, UK). Coomassie Blue G-250 and Coomassie Plus protein assay reagents were from Pierce (Chester, UK). Scintillation fluid was from National Diagnostics (Atlanta, GA). Polyvinylidine difluoride membrane was from Pall Europe Ltd. (Portsmouth, UK). Enhanced chemiluminescence (ECL) reagent was from Amersham Biosciences (Buckinghamshire, UK). Silica gel 60 thin-layer chromatography plates were from Whatman (Maidstone, UK). Anti-perilipin antibody and adenovirus-perilipin A were as described previously (18, 19). Recombinant beta-galactosidase adenovirus (Ad-beta-gal) (a kind gift from Dr. Calum Sutherland, University of Dundee) was generated as described previously (20). Antidesmin antibodies were from Dako (High Wycombe, UK). InfinityTM Triglyceride reagent was from Sigma and 1,2-sn-diacylglyceride reagent kit was from GE Healthcare (Buckinghamshire, UK). [U-14C]-D-Glucose (10 GBq/mmol) and [{gamma}-32P]ATP (~0.11 TBq/mmol) were from GE Healthcare.

Cell Culture—Human myoblasts were grown as described previously (21) from needle biopsies taken from the vastus lateralis muscle of healthy subjects with no family history of Type 2 diabetes and normal glucose tolerance and insulin sensitivity. All subjects gave informed consent and the study was approved by the Newcastle and North Tyneside Joint Ethics Committee. Myoblasts were maintained in Ham's F-10 supplemented with 20% (v/v) fetal calf serum, 1% (v/v) chick embryo extract, 100 units/ml penicillin, and 100 µg/ml streptomycin. All experiments were performed using cells between the 5th and 15th pass, at ~90% confluence. Immunocytochemical staining with anti-desmin antibody confirmed that the cultures were predominantly myoblasts.

Adenoviral Infection of Human Myoblasts—Myoblasts were infected at ~70% confluence. Cells were incubated in 500 µl serum-free Ham's F-10 (containing 100 units/ml penicillin and 100 µg/ml streptomycin) at multiplicity of infection (m.o.i.) of 20–100 virus particles/cell for 2 h. Medium was replaced with growth medium and assays were performed, or cell extracts prepared, after 48 h.

Fatty Acid Preparation and Treatment—Stock solutions (10 mM) of oleate and palmitate, complexed to 12% (w/v) BSA, were prepared. Fatty acids were dissolved in 4 ml of ethanol supplemented with 100 µl of 5 M NaCl and dried under nitrogen prior to resuspension in 150 mM NaCl, 50 mM Tris-HCl, pH 7.9. An optically clear solution was obtained upon heating to 60 °C with continuous agitation and an equal volume of ice-cold 24% FA-free BSA was immediately added. Samples were stored at -20 °C until required. Fatty acid stocks were diluted to appropriate concentrations in serum-free Ham's F-10 medium. Cells were washed three times with PBS prior to the addition of fatty acid-containing medium. Control cells were incubated in serum-free Ham's F-10 medium containing an equivalent concentration of BSA.

Preparation of Cell Extracts for Immunoblotting—Cells were washed with ice-cold PBS and scraped into extraction buffer (100 mM Tris-HCl, pH 7.4, 100 mM KCl, 2 mM EDTA, 25 mM KF, 0.1% (v/v) Triton X-100, 1 mM benzamidine, 0.1 mM NaVO4, 1 µg/ml antipain, 1 µg/ml pepstatin, and 1 µg/ml leupeptin). Extracts were sonicated for 5 s at 3 µm amplitude (Soniprep 150, Sanyo). Protein concentration was determined using a dye binding method (22). Samples (10 µg of protein) were mixed with 4x sample buffer (0.25 M Tris-HCl, pH 6.8, 8% (w/v) SDS, 40% (v/v) glycerol, 20% beta-mercaptoethanol, 0.004% bromphenol blue), boiled for 5 min, and dispersed by sonication for 5 min (Sonibath, Dawe). Extracts were resolved on 10% (w/v) acrylamide gels by SDS-PAGE and immunoblotted as described previously (21).

Oil Red O Staining—Lipids in myoblasts were visualized by histochemical staining with Oil Red O. Cells were rinsed and fixed in 60% isopropyl alcohol for 10 min then stained in 2% (w/v) Oil Red O for 5 min at room temperature. Excess stain was removed by washing in 60% isopropyl alcohol, followed by several changes of distilled water. Stained cells were visualized under a light microscope.

Measurement of Glycogen Synthesis—The rate of glycogen synthesis was determined by measuring the incorporation of [U-14C]glucose into glycogen as described previously (21). FA-treated cells were incubated in serum-free Ham's F-10 supplemented with 400 µM of fatty acid, 0.5% (w/v) BSA for 18 h.

Lipid Quantification—TG content was determined in cell extracts in a buffer of 50 mM Tris, 100 mM KCl, 20 mM KF, 0.5 mM EDTA, and 0.05% (v/v) Lubrol PX, pH 7.9, sonicated three times for 5 s (Soniprep 150). Homogenates were centrifuged at 11,000 x g for 15 min and supernatants collected. Total TG was measured enzymatically with InfinityTM Triglyceride kit, using trioleolylglycerol as standard. For measurement of DAG and ceramide concentrations, myoblasts were scraped into ice-cold PBS and standardized for protein concentration. Samples (100 µg protein) were transferred to polypropylene tubes and lipids extracted by adding 3 ml of ice-cold chloroform:methanol (1:2 v/v) and vortexing vigorously. NaCl (1 M) was added to bring the aqueous volume to 0.8 ml. Chloroform (1 ml) and 1 M NaCl (1 ml) were added to separate the phases. Following centrifugation at 5000 x g for 2 min, the lower chloroform phase was assayed for DAG and ceramide content using a radiometric DAG assay kit (Amersham Biosciences). Samples were applied to silica gel thin-layer plates, along with DAG and ceramide standards. Plates were developed in a tank presaturated with developing solvent (chloroform:acetic acid:acetone:methanol: water; 50:40:20:20:5). Plates were dried, and the zone corresponding to [32P] phosphatidic acid and [32P]ceramide 1-phosphate was visualized by autoradiography. Lipids were stained in iodine vapor, and spots corresponding to phosphatidic acid and ceramide 1-phosphate were scraped into scintillation vials and radioactivity determined.

Statistical Analyses—Data were expressed as means ± S.E. Significance was assessed using a two-tailed unpaired Student's t test following analysis of variance. Sample sizes and p values for particular experiments are given in figure legends.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Perilipin, originally described as an adipocyte-specific protein, has now been detected in a number of tissues, located primarily on the surface of intracellular lipid droplets (23, 24). It has been demonstrated that perilipin promotes lipid accumulation by protecting nascent lipid from hydrolysis by endogenous lipases (18, 25). In view of this, recombinant adenovirus encoding mouse perilipin A was used to infect myoblasts, to promote lipid accumulation. Perilipin A expression was detected 48 h after infection, with the level of protein expression increasing with increasing m.o.i. (Fig. 1A). Using an m.o.i. of 50 virus particles/cell, the effect of ectopic perilipin expression on lipid accumulation was studied. As can be seen in Fig. 1B, expression of perilipin A led to significant accumulation of intracellular lipid, as visualized by staining with Oil Red O. Enzymatic analysis of lipid extracted from these cells showed that they contained ~3 times more triacylglycerol than cells infected with a control adenovirus encoding beta-galactosidase (Fig. 1C). There was no detectable increase in the content of diacylglycerol or ceramide (Fig. 1C).

The effect of insulin on the rate of glycogen synthesis in these cells was then examined, since this is the key physiological end point response for glucose disposal in muscle (Fig. 2). In untreated cells, insulin stimulated glycogen synthesis ~4-fold. Following infection with adenovirus encoding beta-galactosidase, insulin-stimulated glycogen synthesis was essentially unchanged. In the cells expressing perilipin A and with increased triacylglycerol content, again the effect of insulin on rate of glycogen synthesis was undiminished, with both basal and insulin-stimulated rates being unaltered. These data indicate clearly that intracellular triacylglycerol accumulation per se does not cause insulin resistance in this experimental system.

Incubation of myoblasts with individual fatty acids also lead to significant accumulation of intracellular lipid, as visualized by histochemical staining (data not shown) and by enzymatic analysis for triacylglycerol (Fig. 3A). Both oleate and palmitate (respectively the major monounsaturated and saturated fatty acids in serum) caused significant accumulation of triacylglycerol. However, the levels in response to oleate were ~4-fold higher that those formed in response to palmitate. The insulin sensitivity of these lipid-loaded cells was then investigated (Fig. 3B). Insulin stimulated glycogen synthesis ~4-fold in control cells, and this effect was maintained in cells pretreated with oleate. Neither basal nor insulin-stimulated rates of glycogen synthesis were altered, despite the high levels of intracellular triacylglycerol. In contrast, pretreatment of the cells with palmitate caused a significant diminution in the response to insulin (the basal rate of glycogen synthesis was unaltered), despite the fact that the levels of triacylglycerol were lower than these formed in response to oleate. Taken together, these findings again indicate that intracellular triacylglycerol does not induce insulin resistance. However, incubation of cells with palmitate did render cells insulin-resistant, likely via the action of a metabolite derived from this fatty acid.


Figure 1
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 1.
Effect of overexpression of perilipin on lipid accumulation. A, myoblasts were infected with Ad-perilipin at the indicated m.o.i. for 2 h. Cell extracts were prepared after 48 h, and 10 µg of protein was analyzed by immunoblotting using anti-perilipin antibodies. Similar results were obtained in four independent experiments on cells from 3 subjects. B, myoblasts were infected with Ad-beta-Gal or Ad-perilipin at an m.o.i. of 50 virus particles per cell for 2 h. After a further 48 h, cells were fixed in 60% isopropyl alcohol and stained for neutral lipid with Oil Red O. Similar results were obtained in independent experiments on cells from three subjects. C, Myoblasts were treated as above, and cell extracts were prepared and assayed for triacylglycerol, DAG or ceramide. Ceramide and DAG contents were measured by incubating lipid extracts with DAG kinase and [32P]ATP. Lipids were re-extracted, resolved by TLC, and detected by autoradiography. Spots corresponding to 1,2-DAG and ceramide were quantified by liquid scintillation counting. Results are expressed as fold over control (BSA values 135.8 pmol of DAG/mg of protein and 30.5 pmol of ceramide/mg of protein) and are means ± S.E. of four experiments in cells from three subjects. Statistical significance (p < 0.01) compared with respective values in the absence of perilipin is indicated by *.

 


Figure 2
View larger version (25K):
[in this window]
[in a new window]

  		FIGURE 2.
Effect of perilipin overexpression on glycogen synthesis. Myoblasts were infected with either Ad-Perilipin or Ad-beta-gal at MOI of 50 virus particles per cell for 2 h. After 46 h cells were serum-starved for 2 h before glycogen synthesis was measured in the absence or presence of 100 nM insulin over 1 h. Data represent the mean ± S.E. of four independent experiments in cells from three different subjects. Statistical significance (p < 0.01) compared with respective values in the absence of insulin is indicated by *.

 
Both oleate and palmitate can be esterified to DAG in addition to TG. Furthermore, palmitate is a precursor of ceramides. As both DAG and ceramides have known signaling functions, activating for example different isoforms of protein kinase C (26–28), their levels were investigated in cells preincubated with oleate and palmitate. As seen in Fig. 3, C and D, oleate treatment caused little, if any, alteration in the levels of DAG and ceramide, consistent with a preference for triacylglycerol synthesis from this fatty acid. In contrast, palmitate caused marked elevation in the amounts of DAG and ceramide, increasing them 6- and 3.5-fold, respectively. The observation that oleate, which causes mainly TG accumulation, does not induce insulin-resistance is again consistent with TG not being responsible for insulin resistance. In contrast, the finding that palmitate causes insulin resistance indicates that this may be due to one or both of its major lipid metabolites, namely DAG and ceramide.

De novo ceramide synthesis occurs via palmitoyl-CoA and requires the activity of two enzymes, i.e. serine palmitoyltransferase and ceramide synthase (16), which can be specifically inhibited by myriocin and fumonisin B1, respectively. To investigate therefore whether DAG or ceramide was the active agent in inducing insulin resistance, cells were incubated with palmitate in the presence or absence of each inhibitor. As can be seen in Fig. 4A, palmitate again induced insulin resistance, causing a dramatic decrease in the stimulation of glycogen synthesis by the hormone. The stimulation by insulin was unaffected by either inhibitor alone. However, when either inhibitor was present during palmitate treatment, insulin resistance was prevented. As expected, each inhibitor also prevented palmitate-induced ceramide accumulation (Fig. 4B) but did not prevent DAG accumulation caused by the fatty acid (Fig. 4C). These data indicate that ceramide was the agent responsible for inducing insulin resistance. This conclusion was further supported by use of C2-ceramide, a short-chain cell-permeable ceramide analogue. As seen in Fig. 5, treatment of myoblasts with this analogue completely abolished the stimulatory effect of insulin on the rate of glycogen synthesis. Use of the corresponding biologically inert analogue, C2-dihydroceramide, had no effect on the stimulation of glycogen synthesis by insulin.


Figure 3
View larger version (20K):
[in this window]
[in a new window]

  		FIGURE 3.
Effect of fatty acids on glycogen synthesis and lipid accumulation. Myoblasts were incubated in serum free medium supplemented with either 400 µM oleate or 400 µM palmitate for 18 h. Control wells contained 0.5% (w/v) BSA. A, fatty acids were washed away prior to determination of glycogen synthesis in the absence or presence of 100 nM insulin over 1 h. The results represent mean ± S.E. of four experiments in cells from four different subjects. Statistical significance (p < 0.01) compared with control values (BSA) in the presence of insulin is indicated by *. B, cells were treated as above and cell extracts prepared, and triacylglycerol concentration was determined. Results are mean ± S.E. of n = 9 in cells from four different subjects. Significant difference (p < 0.01) compared with control (BSA) is indicated by *, and statistical significance (p < 0.01) compared with cells treated with oleate is indicated by #. DAG (C) and ceramide (D) contents were measured as above. Results are expressed as fold over control and are means ± S.E. of four experiments in cells from three subjects. Significant difference (p < 0.01) compared with control is indicated by *.

 


Figure 4
View larger version (16K):
[in this window]
[in a new window]

  		FIGURE 4.
Effect of inhibiting de novo ceramide synthesis on inhibition of glycogen synthesis by palmitate. A, myoblasts were incubated for 18 h in serum-free medium containing either 0.5% (w/v) BSA or 400 µM palmitate as indicated, in the absence (solid bars) or presence of 10 µM myriocin (open bars)or 50 µM fumonisin B1 (hatched bars). The rate of glycogen synthesis was measured in the absence or presence of 100 nM insulin. Data represent the average ± S.E. of four experiments in three subjects. Significant difference (p < 0.01) compared with control in the presence of insulin is indicated by *. B and C, Myoblasts were incubated for 18 h in serum-free medium containing either 0.5% (w/v) BSA (open bars) or 400 µM palmitate (solid bars) as indicated, in the absence or presence of 10 µM myriocin or 50 µM fumonisin B1 as indicated. Ceramide (B) and DAG (C) were measured as described above. Results are expressed as fold over control and are means ± S.E. of four experiments in cells from three subjects. Statistical significance (p < 0.01) compared with respective control values is indicated by *.

 


Figure 5
View larger version (15K):
[in this window]
[in a new window]

  		FIGURE 5.
Effect of cell-permeable ceramide analogues on rate of glycogen synthesis. Myoblasts were serum-starved for 2 h in the absence (solid bars) or presence of 100 µM C2-ceramide (checked bars) or C2-dihydroceramide (open bars). The rate of glycogen synthesis in the absence or presence of 100 nM insulin was then determined. Results are the mean ± S.E. of four experiments in cells from at least three subjects. Statistical difference (p < 0.05) compared with respective values in the absence of insulin is indicated by *. # indicates significant difference (p < 0.05) compared with control values in the absence of insulin.

 
The observation that oleate caused significant accumulation of TG and yet did not induce insulin resistance raised the possibility that the presence of oleate might protect the cells against the effects of palmitate by directing fatty acids into TG rather than ceramide synthesis. Indeed, co-incubation of muscle cells with oleate and palmitate for 18 h caused a significant increase in TG accumulation (843 ± 64 µg/mg protein) compared with palmitate (620 ± 35 µg/mg protein) treatment alone (p < 0.05).

Co-incubation of cells with both fatty acids virtually abolished accumulations of both DAG and ceramide that were observed after incubating cells with palmitate alone (Figs. 6, A and B).

Fig. 6C shows that co-incubation with oleate prevented the inhibitory effects of palmitate on insulin-stimulated glycogen synthesis.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
We have presented several lines of evidence to suggest that intracellular accumulation of ceramides can invoke insulin resistance in the key end point response of glycogen synthesis in cultured human myoblasts. Furthermore, we present evidence that intracellular accumulation of TG or DAG does not in itself lead to insulin resistance and indeed that intracellular TG may exert a protective role against insulin resistance induced by saturated fatty acids.


Figure 6
View larger version (13K):
[in this window]
[in a new window]

  		FIGURE 6.
Protective effect of oleate co-incubation on the effect of palmitate on glycogen synthesis. Myoblasts were incubated for 18 h in serum-free medium containing either 0.5% (w/v) BSA, 400 µM palmitate, or a combination of 400 µM palmitate and 400 µM oleate. DAG (A) and ceramide (B) content were determined as described above. Results are expressed as fold over control and are means ± S.E. of four experiments in cells from three subjects. Statistical significance (p < 0.01) compared with respective control values is indicated by *. C, glycogen synthesis was measured in the absence (open bars) or presence (solid bars) of 100 nM insulin over 1 h. The results represent the mean ± S.E. of four experiments in cells from at least three subjects. Statistical significance (p < 0.01) compared with control (BSA alone) in the presence of insulin is indicated by *.

 
Although numerous studies have associated increased IMTG with insulin resistance, the evidence reported herein indicate that the IMTG itself is not responsible. Perhaps the clearest demonstration of this is the effect of adenovirus-driven perilipin expression. Although perilipin is not normally present in muscle (29), when perilipin is expressed, the balance between TG synthesis and lipolysis is disturbed, leading to lipid accumulation. This occurred in the presence of levels of endogenous lipids in the serum used for cell culture, showing that the transduced myoblasts had the ability to accumulate lipids without any necessity for elevated extracellular lipid concentrations. Furthermore, these experiments demonstrate a novel mechanism for elevation of IMTG without significant changes in DAG or ceramide.

Since both DAG and ceramide were elevated by palmitate treatment, it was necessary to ascertain which of these metabolites were responsible for the insulin resistance observed. To this end, we used myriocin and fumonisin B1 to specifically inhibit distinct enzymes involved in the biosynthesis of ceramide from palmitate. Each inhibitor prevented palmitate-induced insulin resistance. Furthermore, the addition of exogenous, cell-permeable ceramide replicated the deleterious effect of palmitate on insulin-sensitive glycogen synthesis. Together, these data provide strong evidence that the production of ceramide from palmitate is necessary for the induction of insulin resistance, consistent with recent studies performed in rodent cell lines (17, 30, 31).

Ceramide is known to have a significant impact upon a number of different intracellular signaling events important in mediating insulin action, in addition to the effects on PKB described above. Increased ceramide is also associated with processes such as oxidative stress, inflammation, and apoptosis (32). However, it is not yet established which of these are important in the mechanism by which ceramides induce insulin resistance in muscle cells. Future studies will aim to identify the molecular events that are instrumental in the mechanism of insulin resistance in this model system.

A crucial question is of course whether ceramides mediate insulin resistance in vivo. Several lines of evidence indicate that this is indeed the case. Insulin-resistant Zucker rats (4) contain elevated skeletal muscle ceramide levels, and recent findings have demonstrated elevated ceramide content in skeletal muscle from insulin-resistant humans (11, 33). Other workers have reported fatty acid-induced insulin resistance in the absence of increases in ceramide (34, 35). Such studies were performed using lipid emulsions such as Liposyn II, made from mainly unsaturated fats that are not substrates for ceramide synthesis. A number of alternative mechanisms have been proposed for insulin resistance induced by unsaturated fats, including roles for protein kinase C and tumor necrosis factor {alpha}, as discussed by Summers (32).

A key aspect of the current work is the observation that accumulated intracellular triacylglycerol may exert a protective role against the insulin resistance induced by palmitate. A similar effect was reported by Montell and colleagues (9) who showed that palmitate antagonized insulin stimulation of glucose uptake in human myotubes but that the insulin response was restored in cells treated with a mixture of oleate and palmitate. Unlike in the present study, these authors concluded that DAG played a role in saturated fatty acid-induced insulin resistance, and oleate prevented this insulin resistance due to its ability to redirect saturated FA away from the DAG pool into TG. However, this study did not consider ceramide accumulation. In addition, Chavez et al. (10) suggested that the resistance of adipocytes to fatty acid-induced insulin resistance is attributable to their increased capacity to sequester fatty acids into TG, while Listenberger et al. (36) demonstrated that TG accumulation protects against saturated fatty acid-induced lipotoxicity in pancreatic beta cells. These observations are consistent with the view that the stored TG "buffers" excess fatty acids arriving at the peripheral tissues such as muscle. Once the capacity of that buffer has been exceeded, the deleterious effects of the fatty acids and their lipid derivatives such as ceramides can be manifested.


   FOOTNOTES
 
* This work was supported partly by Wellcome Trust Grant 066495/Z/01/A, National Institutes of Health Grant IH DK50647 and United States Department of Agriculture-Agricultural Research Service Co-operative Agreement 58 1950-4-401. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 Supported by a Biotechnology and Biological Sciences Research Council Co-operative Award in Science Engineering studentship in collaboration with Xcellsyz Ltd. Present address: Unilever Colworth, Sharnbrook, Bedford MK44 1LQ, UK. Back

2 To whom correspondence should be addressed. Tel.: 44-191-222-7433; Fax: 44-191-222-7424; E-mail: S.J.Yeaman{at}ncl.ac.uk.

3 The abbreviations used are: IMTG, intramyocellular triacylglycerol; DAG, diacylglycerol; FA, fatty acid; NEFA, non-esterified fatty acid; m.o.i., multiplicity of infection; PKB, protein kinase B; TG, triacylglycerol; BSA, bovine serum albumin. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ohlson, L. O., Larsson, B., Svardsudd, K., Welin, L., Eriksson, H., Wilhelmsen, L., Bjorntorp, P., and Tibblin, G. (1985) Diabetes 34, 1055-1058[Abstract]
  2. (2000) Arch. Intern. Med. 160, 898-904[Abstract/Free Full Text]
  3. Thamer, C., Machann, J., Bachmann, O., Haap, M., Dahl, D., Wietek, B., Tschritter, O., Niess, A., Brechtel, K., Fritsche, A., Claussen, C., Jacob, S., Schick, F., Haring, H. U., and Stumvoll, M. (2003) J. Clin Endocrinol. Metab. 88, 1785-1791[Abstract/Free Full Text]
  4. Turinsky, J., O'Sullivan, D. M., and Bayly, B. P. (1990) J. Biol. Chem. 265, 16880-16885[Abstract/Free Full Text]
  5. Chen, K. S., Heydrick, S., Kurowski, T., and Ruderman, N. B. (1991) Trans. Assoc. Am. Physicians 104, 206-212[Medline] [Order article via Infotrieve]
  6. Hajduch, E., Balendran, A., Batty, I. H., Litherland, G. J., Blair, A. S., Downes, C. P., and Hundal, H. S. (2001) Diabetologia 44, 173-183[CrossRef][Medline] [Order article via Infotrieve]
  7. Teruel, T., Hernandez, R., and Lorenzo, M. (2001) Diabetes 50, 2563-2571[Abstract/Free Full Text]
  8. Wang, C. N., O'Brien, L., and Brindley, D. N. (1998) Diabetes 47, 24-31[Abstract]
  9. Montell, E., Turini, M., Marotta, M., Roberts, M., Noe, V., Ciudad, C. J., Mace, K., and Gomez-Foix, A. M. (2001) Am. J. Physiol. 280, E229-E237
  10. Chavez, J. A., and Summers, S. A. (2003) Arch. Biochem. Biophys. 419, 101-109[CrossRef][Medline] [Order article via Infotrieve]
  11. Adams, J. M., II, Pratipanawatr, T., Berria, R., Wang, E., DeFronzo, R. A., Sullards, M. C., and Mandarino, L. J. (2004) Diabetes 53, 25-31[Abstract/Free Full Text]
  12. Zhou, H., Summers, S. A., Birnbaum, M. J., and Pittman, R. N. (1998) J. Biol. Chem. 273, 16568-16575[Abstract/Free Full Text]
  13. Kanety, H., Hemi, R., Papa, M. Z., and Karasik, A. (1996) J. Biol. Chem. 271, 9895-9897[Abstract/Free Full Text]
  14. Schmitz-Peiffer, C., Craig, D. L., and Biden, T. J. (1999) J. Biol. Chem. 274, 24202-24210[Abstract/Free Full Text]
  15. Hannun, Y. A., and Obeid, L. M. (2002) J. Biol. Chem. 277, 25847-25850[Free Full Text]
  16. Merrill, A. H., Jr., and Jones, D. D. (1990) Biochim. Biophys. Acta 1044, 1-12[Medline] [Order article via Infotrieve]
  17. Chavez, J. A., Knotts, T. A., Wang, L. P., Li, G., Dobrowsky, R. T., Florant, G. L., and Summers, S. A. (2003) J. Biol. Chem. 278, 10297-10303[Abstract/Free Full Text]
  18. Souza, S. C., de Vargas, L. M., Yamamoto, M. T., Lien, P., Franciosa, M. D., Moss, L. G., and Greenberg, A. S. (1998) J. Biol. Chem. 273, 24665-24669[Abstract/Free Full Text]
  19. Souza, S. C., Muliro, K. V., Liscum, L., Lien, P., Yamamoto, M. T., Schaffer, J. E., Dallal, G. E., Wang, X., Kraemer, F. B., Obin, M., and Greenberg, A. S. (2002) J. Biol. Chem. 277, 8267-8272[Abstract/Free Full Text]
  20. Gabbay, R. A., Sutherland, C., Gnudi, L., Kahn, B. B., O'Brien, R. M., Granner, D. K., and Flier, J. S. (1996) J. Biol. Chem. 271, 1890-1897[Abstract/Free Full Text]
  21. Halse, R., Bonavaud, S. M., Armstrong, J. L., McCormack, J. G., and Yeaman, S. J. (2001) Diabetes 50, 720-726[Abstract/Free Full Text]
  22. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
  23. Greenberg, A. S., Egan, J. J., Wek, S. A., Garty, N. B., Blanchette-Mackie, E. J., and Londos, C. (1991) J. Biol. Chem. 266, 11341-11346[Abstract/Free Full Text]
  24. Blanchette-Mackie, E. J., Dwyer, N. K., Barber, T., Coxey, R. A., Takeda, T., Rondinone, C. M., Theodorakis, J. L., Greenberg, A. S., and Londos, C. (1995) J. Lipid Res. 36, 1211-1226[Abstract]
  25. Brasaemle, D. L., Rubin, B., Harten, I. A., Gruia-Gray, J., Kimmel, A. R., and Londos, C. (2000) J. Biol. Chem. 275, 38486-38493[Abstract/Free Full Text]
  26. Huwiler, A., Fabbro, D., and Pfeilschifter, J. (1998) Biochemistry 37, 14556-14562[CrossRef][Medline] [Order article via Infotrieve]
  27. Wang, Y. M., Seibenhener, M. L., Vandenplas, M. L., and Wooten, M. W. (1999) J. Neurosci. Res. 55, 293-302[CrossRef][Medline] [Order article via Infotrieve]
  28. Way, K. J., Katai, N., and King, G. L. (2001) Diabet. Med. 18, 945-959[CrossRef][Medline] [Order article via Infotrieve]
  29. Phillips, S. A., Choe, C. C., Ciaraldi, T. P., Greenberg, A. S., Kong, A. P., Baxi, S. C., Christiansen, L., Mudaliar, S. R., and Henry, R. R. (2005) Obes. Res. 13, 1321-1329[Medline] [Order article via Infotrieve]
  30. Powell, D. J., Turban, S., Gray, A., Hajduch, E., and Hundal, H. S. (2004) Biochem. J. 382, 619-629[CrossRef][Medline] [Order article via Infotrieve]
  31. Chavez, J. A., Holland, W. L., Bar, J., Sandhoff, K., and Summers, S. A. (2005) J. Biol. Chem. 280, 20148-20153[Abstract/Free Full Text]
  32. Summers, S. A. (2006) Prog. Lipid Res. 45, 42-72[CrossRef][Medline] [Order article via Infotrieve]
  33. Straczkowski, M., Kowalska, I., Nikolajuk, A., Dzienis-Straczkowska, S., Kinalska, I., Baranowski, M., Zendzian-Piotrowska, M., Brzezinska, Z., and Gorski, J. (2004) Diabetes 53, 1215-1221[Abstract/Free Full Text]
  34. Griffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D., Goodyear, L. J., Kraegen, E. W., White, M. F., and Shulman, G. I. (1999) Diabetes 48, 1270-1274[Abstract]
  35. Itani, S. I., Ruderman, N. B., Schmieder, F., and Boden, G. (2002) Diabetes 51, 2005-2011[Abstract/Free Full Text]
  36. Listenberger, L. L., Han, X., Lewis, S. E., Cases, S., Farese, R. V., Jr., Ory, D. S., and Schaffer, J. E. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 3077-3082[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D.-E. Lee, S. Kehlenbrink, H. Lee, M. Hawkins, and J. S. Yudkin
Getting the message across: mechanisms of physiological cross talk by adipose tissue
Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1210 - E1229.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. M. Deevska, K. A. Rozenova, N. V. Giltiay, M. A. Chambers, J. White, B. B. Boyanovsky, J. Wei, A. Daugherty, E. J. Smart, M. B. Reid, et al.
Acid Sphingomyelinase Deficiency Prevents Diet-induced Hepatic Triacylglycerol Accumulation and Hyperglycemia in Mice
J. Biol. Chem., March 27, 2009; 284(13): 8359 - 8368.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A.-L. Tardy, C. Giraudet, P. Rousset, J.-P. Rigaudiere, B. Laillet, S. Chalancon, J. Salles, O. Loreau, J.-M. Chardigny, and B. Morio
Effects of trans MUFA from dairy and industrial sources on muscle mitochondrial function and insulin sensitivity
J. Lipid Res., July 1, 2008; 49(7): 1445 - 1455.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
W. L. Holland and S. A. Summers
Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism
Endocr. Rev., June 1, 2008; 29(4): 381 - 402.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Coll, E. Eyre, R. Rodriguez-Calvo, X. Palomer, R. M. Sanchez, M. Merlos, J. C. Laguna, and M. Vazquez-Carrera
Oleate Reverses Palmitate-induced Insulin Resistance and Inflammation in Skeletal Muscle Cells
J. Biol. Chem., April 25, 2008; 283(17): 11107 - 11116.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Moro, S. Bajpeyi, and S. R. Smith
Determinants of intramyocellular triglyceride turnover: implications for insulin sensitivity
Am J Physiol Endocrinol Metab, February 1, 2008; 294(2): E203 - E213.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/17/12583    most recent
M611157200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pickersgill, L.
Right arrow Articles by Yeaman, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pickersgill, L.
Right arrow Articles by Yeaman, S. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement